

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/125527 A1

(51) International Patent Classification:

A61K 31/341 (2006.01) *A61P 21/04* (2006.01)
A61K 31/7076 (2006.01) *A61K 9/48* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/EP2024/086103

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,175	14 December 2023 (14.12.2023)	US
63/658,170	10 June 2024 (10.06.2024)	US
63/679,861	06 August 2024 (06.08.2024)	US

(71) Applicant: **ARES TRADING S.A.** [CH/CH]; Rue de l'Ouriette 151, Zone Industrielle de l'Ouriettaz, 1170 Aubonne (CH).

(72) Inventors: **BECKER, Andreas D**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **RAVULA, Abhigyan**; c/o EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US). **GOTETI, Kosalaran**; c/o EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US). **ALEXANDRI, Nektaria**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **BOSCHERT SHAFATIAN, Ursula**; c/o Ares Trading S.A., Terre Bonne Business Park - Building Z0, Route de Crassier 1, 1262 Eysins (CH). **KOEHL, Niklas**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **VON BURKERSRODA, Friederike**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **WIEDEY, Raphael**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **ASSI, Pardis**; c/o Almac Pharma Services Limited, 22 Seagoe Industrial Estate, Craigavon Armagh BT63 5QD (GB). **JUNG, Markus**; c/o Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE).

(74) Agent: **MERCK SERONO S.A. INTELLECTUAL PROPERTY**; Terre Bonne Business Park - Building Z0, Route de Crassier 1, 1262 Eysins (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CLADRIBINE REGIMEN FOR TREATING MYASTHENIA GRAVIS

(57) Abstract: The present invention relates to compounds for the treatment of Myasthenia Gravis and related methods and dosing regimen. Specifically, the invention pertains to the field of treatment scheme of oral formulation of cladribine and relevant for the treatment of Myasthenia Gravis, more specifically generalized Myasthenia Gravis.

WO 2025/125527 A1